Data from EMA (European Medicines Agency) - Curated by Toby Galbraith - Last updated 06 July 2017

Indication(s)

Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).

RIXUBIS is indicated in patients of all age groups.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Oral Anticoagulation Reversal

Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.

Visit Oral Anticoagulation Reversal

Transplantation

See information on best practice in solid organ transplantation, and expert discussions on related hot topics.

Visit Transplantation

Related Content

More information

Category Value
Agency product number EMEA/H/C/003771
Orphan designation No
Date First Approved 19-12-2014
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder Baxalta Innovations GmbH